{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T09:03:31Z","timestamp":1780650211142,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZSM202211013"],"award-info":[{"award-number":["SZSM202211013"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.xkme.2026.101336","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T07:35:05Z","timestamp":1773646505000},"page":"101336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research Advances in Rituximab-Resistant Membranous Nephropathy"],"prefix":"10.1016","volume":"8","author":[{"given":"Kaiting","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8822-2844","authenticated-orcid":false,"given":"Qijun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.xkme.2026.101336_bib1","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101336_bib2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1053\/j.ajkd.2023.10.013","article-title":"Anti-phospholipase A2 receptor 1 and anti-cysteine rich antibodies, domain recognition and rituximab efficacy in membranous nephropathy: a prospective cohort study","volume":"83","author":"Ruggenenti","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"4S","key":"10.1016\/j.xkme.2026.101336_bib3","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.xkme.2026.101336_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/ndt\/gfad225","article-title":"Membranous nephropathy treatment standard","volume":"39","author":"Radhakrishnan","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.xkme.2026.101336_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: historical and future perspectives","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.xkme.2026.101336_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.805697","article-title":"New and old anti-CD20 monoclonal antibodies for nephrotic syndrome. Where we are?","volume":"13","author":"Basu","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101336_bib7","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.xkme.2026.101336_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.xkme.2026.101336_bib9","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101336_bib10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/ndt\/gfab316","article-title":"The management of membranous nephropathy-an update","volume":"37","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.xkme.2026.101336_bib11","first-page":"282","article-title":"Expert consensus on the application of rituximab in the treatment of membranous nephropathy]","volume":"61","year":"2022","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"1","key":"10.1016\/j.xkme.2026.101336_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101336_bib13","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2026.101336_bib14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fmed.2020.00412","article-title":"Personalized medicine for PLA2R1-related membranous nephropathy: a multicenter randomized control trial","volume":"7","author":"Brglez","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.xkme.2026.101336_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1060028018803587","article-title":"Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy","volume":"53","author":"Fogueri","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.xkme.2026.101336_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/1078-0432.CCR-10-1292","article-title":"Interindividual variability of response to rituximab: from biological origins to individualized therapies","volume":"17","author":"Cartron","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.xkme.2026.101336_bib17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jim.2017.09.001","article-title":"Detection and quantification of rituximab in the human urine","volume":"451","author":"Jacobs","year":"2017","journal-title":"J Immunol Methods"},{"issue":"2","key":"10.1016\/j.xkme.2026.101336_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ard.2009.109041","article-title":"Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.xkme.2026.101336_bib19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","article-title":"Rituximab bioavailability in primary membranous nephropathy","volume":"34","author":"Boyer-Suavet","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"25","key":"10.1016\/j.xkme.2026.101336_bib20","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.xkme.2026.101336_bib21","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/art.39167","article-title":"Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus","volume":"67","author":"Reddy","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.xkme.2026.101336_bib22","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.xkme.2026.101336_bib23","first-page":"189","article-title":"B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia","volume":"87","author":"Zaja","year":"2002","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.xkme.2026.101336_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"issue":"589","key":"10.1016\/j.xkme.2026.101336_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.xkme.2026.101336_bib26","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.xkme.2026.101336_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101336_bib28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.0000000000000152","article-title":"Risk factors associated with the occurrence of anti-rituximab antibodies in membranous nephropathy","volume":"18","author":"Teisseyre","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101336_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2017070734","article-title":"Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy","volume":"29","author":"Seitz-Polski","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101336_bib30","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101336_bib31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.xkme.2026.101336_bib32","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101336_bib33","first-page":"347","article-title":"Epitope spreading: a mechanism for progression of autoimmune disease","volume":"48","author":"Tuohy","year":"2000","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"5","key":"10.1016\/j.xkme.2026.101336_bib34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.xkme.2026.101336_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101336_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1515\/cclm-2022-0720","article-title":"Quantitative detection of anti-PLA2R antibodies targeting different epitopes and its clinical application in primary membranous nephropathy","volume":"61","author":"Qin","year":"2023","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"10.1016\/j.xkme.2026.101336_bib37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1681\/ASN.2019030273","article-title":"Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy","volume":"31","author":"Reinhard","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101336_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0302100","article-title":"Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: a retrospective study","volume":"19","author":"Zhou","year":"2024","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.xkme.2026.101336_bib39","doi-asserted-by":"crossref","first-page":"6868","DOI":"10.1038\/s41598-025-91366-5","article-title":"Role of PLA2R domain antibodies and epitope spreading in risk stratification and prediction of proteinuria remission in primary membranous nephropathy","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"issue":"9337","key":"10.1016\/j.xkme.2026.101336_bib40","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.xkme.2026.101336_bib41","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1097\/01.ASN.0000071511.35221.B3","article-title":"Rituximab in idiopathic membranous nephropathy: a one-year prospective study","volume":"14","author":"Ruggenenti","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101336_bib42","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2215\/CJN.01080905","article-title":"Rituximab for idiopathic membranous nephropathy: who can benefit?","volume":"1","author":"Ruggenenti","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.xkme.2026.101336_bib43","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1016\/j.xkme.2026.101336_bib44","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ekir.2024.05.004","article-title":"Obinutuzumab as initial or second-line therapy in patients with primary membranous nephropathy","volume":"9","author":"Su","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"12","key":"10.1016\/j.xkme.2026.101336_bib45","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2215\/CJN.0000000000000555","article-title":"Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy","volume":"19","author":"Hu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101336_bib46","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/ndt\/gfae230","article-title":"Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy","volume":"40","author":"Xu","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.xkme.2026.101336_bib47","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s40620-025-02224-6","article-title":"Obinutuzumab in rituximab-resistant and recurrent membranous nephropathy: a case-series","volume":"38","author":"Sridharan","year":"2025","journal-title":"J Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101336_bib48","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: a report of 3 cases","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.xkme.2026.101336_bib49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-022-02761-3","article-title":"Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases","volume":"23","author":"Hudson","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.xkme.2026.101336_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab-the world\u2019s first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101336_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-232896","article-title":"Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness","volume":"13","author":"Podest\u00e0","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.xkme.2026.101336_bib52","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.ajkd.2023.08.010","article-title":"Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series","volume":"83","author":"Podest\u00e0","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.xkme.2026.101336_bib53","doi-asserted-by":"crossref","first-page":"17050","DOI":"10.1002\/jcp.28445","article-title":"The role of BAFF and APRIL in rheumatoid arthritis","volume":"234","author":"Shabgah","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.xkme.2026.101336_bib54","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8483650","article-title":"Serum levels of BAFF and APRIL predict clinical response in anti-PLA2R-positive primary membranous nephropathy","volume":"2019","author":"Netti","year":"2019","journal-title":"J Immunol Res"},{"issue":"3","key":"10.1016\/j.xkme.2026.101336_bib55","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3390\/ijms26030929","article-title":"Advances in targeted therapy for systemic lupus erythematosus: current treatments and novel approaches","volume":"26","author":"Saegusa","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.xkme.2026.101336_bib56","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ndt\/gfz086","article-title":"Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy","volume":"35","author":"Barrett","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.xkme.2026.101336_bib57","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.xkme.2026.101336_bib58","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.xkme.2026.101336_bib59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.seminoncol.2021.11.002","article-title":"Current and prospective antibody-based therapies in multiple myeloma","volume":"49","author":"Bryer","year":"2022","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.xkme.2026.101336_bib60","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.kint.2021.12.019","article-title":"Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy","volume":"101","author":"Vink","year":"2022","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.xkme.2026.101336_bib61","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.kint.2021.11.001","article-title":"Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression","volume":"101","author":"Stehl\u00e9","year":"2022","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.xkme.2026.101336_bib62","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ekir.2024.06.018","article-title":"Phase 1b\/2a study assessing the safety and efficacy of felzartamab in anti-phospholipase A2 receptor autoantibody-positive primary membranous nephropathy","volume":"9","author":"Rovin","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.xkme.2026.101336_bib63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40620-013-0028-x","article-title":"Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy","volume":"27","author":"Hartono","year":"2014","journal-title":"J Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101336_bib64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000515087","article-title":"Bortezomib treatment for refractory PLA2R-positive membranous nephropathy","volume":"1","author":"Geara","year":"2021","journal-title":"Glomerular Dis"},{"issue":"3","key":"10.1016\/j.xkme.2026.101336_bib65","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.kint.2021.04.011","article-title":"Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy","volume":"100","author":"Salhi","year":"2021","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.xkme.2026.101336_bib66","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","article-title":"Membranous nephropathy: new pathogenic mechanisms and their clinical implications","volume":"18","author":"Hoxha","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.xkme.2026.101336_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1009864","article-title":"The role of the complement system in primary membranous nephropathy: a narrative review in the era of new therapeutic targets","volume":"13","author":"So","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.xkme.2026.101336_bib68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.molimm.2020.10.017","article-title":"Is primary membranous nephropathy a complement mediated disease?","volume":"128","author":"Reinhard","year":"2020","journal-title":"Mol Immunol"},{"key":"10.1016\/j.xkme.2026.101336_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.909503","article-title":"Post-transplant thrombotic microangiopathy due to a pathogenic mutation in complement factor I in a patient with membranous nephropathy: case report and review of literature","volume":"13","author":"Saleem","year":"2022","journal-title":"Front Immunol"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259005952600097X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259005952600097X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:14:17Z","timestamp":1780647257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259005952600097X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S259005952600097X"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101336","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research Advances in Rituximab-Resistant Membranous Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101336"}}